IQVIA Holdings Inc. (NYSE:IQV) Given Consensus Rating of “Moderate Buy” by Analysts

IQVIA Holdings Inc. (NYSE:IQV) has been given an average recommendation of “Moderate Buy” by the twenty-four brokerages that are currently covering the firm, MarketBeat reports. Seven equities research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $237.62.

A number of research firms have commented on IQV. Mizuho decreased their target price on IQVIA from $242.00 to $210.00 and set an “outperform” rating on the stock in a research report on Wednesday, April 9th. JPMorgan Chase & Co. lowered their price objective on shares of IQVIA from $240.00 to $232.00 and set an “overweight” rating on the stock in a research note on Tuesday, February 18th. HSBC cut shares of IQVIA from a “buy” rating to a “hold” rating and cut their target price for the stock from $260.00 to $160.00 in a research report on Friday, April 25th. Citigroup lowered their price target on shares of IQVIA from $225.00 to $210.00 and set a “neutral” rating on the stock in a research report on Tuesday, March 4th. Finally, Royal Bank of Canada restated an “outperform” rating and set a $270.00 price objective on shares of IQVIA in a research report on Monday, February 10th.

IQVIA Trading Down 0.8 %

Shares of IQV stock opened at $152.31 on Tuesday. IQVIA has a 1-year low of $135.97 and a 1-year high of $252.88. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84. The business’s fifty day moving average price is $166.75 and its 200 day moving average price is $190.17. The firm has a market capitalization of $26.85 billion, a PE ratio of 20.31, a P/E/G ratio of 1.99 and a beta of 1.34.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. As a group, sell-side analysts forecast that IQVIA will post 10.84 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of IQV. Howard Capital Management Inc. boosted its position in IQVIA by 4.9% during the 4th quarter. Howard Capital Management Inc. now owns 1,147 shares of the medical research company’s stock worth $225,000 after purchasing an additional 54 shares during the period. Wealth Enhancement Advisory Services LLC lifted its position in IQVIA by 1.0% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 5,434 shares of the medical research company’s stock worth $1,068,000 after acquiring an additional 56 shares in the last quarter. Cypress Wealth Services LLC grew its holdings in IQVIA by 4.8% during the 4th quarter. Cypress Wealth Services LLC now owns 1,243 shares of the medical research company’s stock valued at $244,000 after purchasing an additional 57 shares in the last quarter. Harbor Investment Advisory LLC increased its stake in IQVIA by 4.7% during the 4th quarter. Harbor Investment Advisory LLC now owns 1,286 shares of the medical research company’s stock worth $253,000 after buying an additional 58 shares during the period. Finally, Continuum Advisory LLC lifted its holdings in IQVIA by 3.7% in the 4th quarter. Continuum Advisory LLC now owns 1,803 shares of the medical research company’s stock worth $354,000 after buying an additional 64 shares in the last quarter. 89.62% of the stock is owned by institutional investors and hedge funds.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.